A ustralian and N ew Z ealand S ociety for G eriatric M edicine Position Statement – Immunisation of older people
2016; Wiley; Volume: 35; Issue: 1 Linguagem: Inglês
10.1111/ajag.12213
ISSN1741-6612
Tópico(s)Influenza Virus Research Studies
ResumoAustralasian Journal on AgeingVolume 35, Issue 1 p. 67-73 Position Statement Australian and New Zealand Society for Geriatric Medicine Position Statement – Immunisation of older people First published: 24 March 2016 https://doi.org/10.1111/ajag.12213Citations: 2 This Position Statement represents the views of the Australian and New Zealand Society for Geriatric Medicine. This Statement was first approved by the Federal Council of the ANZSGM on 9 November 2004 and this revision was approved by the Federal Council on 22 August 2011. The revision of this paper was coordinated by Associate Professor Michael Woodward. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1De Ravin JW, Gerrard PN. The effect of influenza on Australian mortality. Annual Transactions of the Australian Institute of Actuaries 1984; 1: 471–479. 2Barker WM, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. American Journal of Epidemiology 1980; 112: 798–811. 3Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2006; (3): CD004876. 4Fedson DS, Nichol KL. Influenza vaccination policy versus evidence. No gap between policy and evidence. British Medical Journal 2006; 333: 1020–1021. 5Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. New England Journal of Medicine 2007; 357: 1373–1381. 6Groewold RHH, Hoes AW, Hak E. Impact of influenza vaccination on mortalilty risk among the elderly. European Respiratory Journal 2009; 34: 56–62. 7Dean AS, Moffat CR, Rosewell A et al. Incompletely matched influenza vaccine still provides protection in frail elderly. Vaccine 2010; 28: 864–867. 8Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low, intermediate and high-risk senior citizens. Archives of Internal Medicine 1998; 158: 1769–1776. 9Ellis SE, Coffey CS, Mithel EF Jr et al. Influenza – and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. Journal of the American Geriatrics Society 2003; 51: 761–767. 10Postma MJ, Baltussen RM, Heijnen M-LA et al. Pharmacoeconomics of influenza vaccination in the elderly. Reviewing the available evidence. Drugs and Aging 2000; 17: 217–223. 11Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly: A randomised, placebo-controlled trial. Journal of the American Medical Association 1990; 264: 1139–1141. 12Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine along with pneumococcal vaccine to the elderly. Archives of Internal Medicine 1996; 156: 205–208. 13Lasky T, Terracciono GJ, Magder L et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. New England Journal of Medicine 1998; 339: 1797–1802. 14 Australian Institute of Health and Welfare. 2003 Influenza Vaccine Survey. Canberra: Australian Government Department of Health and Ageing, 2004. AIHW cat. no. PHE5I. 15Gillick MR, Ditzion B. Influenza vaccination: Are we doing better than we think? Archives of Internal Medicine 1991; 151: 1742–1744. 16Setia U, Sereventi I, Lorenz P. Factors affecting the use of influenza vaccine in the institutionalised elderly. Journal of the American Geriatrics Society 1985; 33: 856–858. 17Nichol KL, Korn JE, Margolis KL et al. Achieving the national health objective for influenza immunisation: Success of an institution-wide vaccination program. The American Journal of Medicine 1990; 89: 156–160. 18Verweij M, van den Hoven M. Influenza vaccination rates and informed consent in Dutch nursing homes: Survey of nursing home physicians. British Medical Journal 2002; 324: 328. DOI: 10.1136/bmj.324.7333.328 19Smith DM, Zhou X-H, Weinberger M, Smith F, McDonald RC. Mailed reminders for area-wide influenza immunisation: A randomized controlled trial. Journal of American Geriatrics Society 1999; 47: 1–5. 20Van Essen GA, Kuyvenhoven MM, DeMeiker RU. Why do healthy elderly people fail to comply with influenza vaccination? Age and Ageing 1997; 26: 275–279. 21Ahmed AH, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet 1995; 346: 591–595. 22Lambert LC, Fauci AS. Influenza vaccines for the future. New England Journal of Medicine 2010; 363: 2036–2044. 23Potter JM, O'Donnell B, Carman WF, Roberts MA, Stott DJ. Serological response to influenza vaccination and nutritional and functional status of patients in geriatric medical long-term care. Age and Ageing 1999; 28: 141–145. 24Allsup SJ, Shenkin A, Gosney MA et al. Can a short period of micronutrient supplementation in older institutionalised people improve response to influenza vaccine? A randomized, controlled trial. Journal of the American Geriatrics Society 2004; 52: 20–24. 25Fedson DS. Influenza and pneumococcal vaccination of the elderly: Newer vaccines and prospects for clinical benefits at the margin. Preventative Medicine 1994; 23: 751–755. 26Couch RB. Prevention and treatment of influenza. New England Journal of Medicine 2000; 343: 1778–1787. 27Hayden FG, Albert DME, Osterhus DUM et al. Efficacy and safety of the neuraminidase inhibitor zanamir in the treatment of influenza virus infections. New England Journal of Medicine 1997; 337: 874–880. 28Peters PH Jr, Gravenstein S, Norwood P et al. Long-term use of oseltamavir for the prophylaxis of influenza in a vaccinated frail population. Journal of American Geriatrics Society 2001; 49: 1025–1031. 29Cooper NJ, Sutton AJ, Abrams KR et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. British Medical Journal 2003; 326: 1235–1240. 30Booy R, Lindley RI, Dwyer DE et al. Treating and preventing influenza in aged care facilities: A cluster randomised controlled trial. PLoS ONE 2012; 7: e46509. doi: 10.1371/journal.pone.0046509. 31Drinka PJ. Influenza vaccination and antiviral therapy. Is there a role for concurrent administration in the institutionalised elderly? Drugs and Ageing 2003; 20: 165–174. 32Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M. Comparison of elderly peoples' technique in using two dry powder inhalers to deliver zanamivir: Randomized controlled trial. British Medical Journal 2001; 322: 577–579. 33Jefferson T, Jones MA, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2012; (1): Art. No.: CD008965, doi: 10.1002/14651858.CD008965.pub3. 34Potter J, Stott DJ, Roberts MA et al. Influenza vaccinations of health care workers in long-term-care hospitals reduces the mortality of elderly patients. Journal of Infectious Diseases 1997; 175: 1–6. 35Nicholson KG. Should staff in long-stay hospitals for elderly patients be vaccinated against influenza? Lancet 2000; 355: 83–84. 36Carman WF, Elder AG, Wallace LA et al. Effects of influenza vaccination of health care workers on mortality of elderly people in long-term care: A randomized controlled trial. Lancet 2000; 355: 93–97. 37Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in health care professionals. A randomized trial. Journal of the American Medical Association 1999; 281: 908–913. 38Thomas DR, Winsted B, Koontz C. Improving neglected influenza vaccination among healthcare workers in long term care. Journal of the American Geriatrics Society 1993; 41: 928–930. 39Hogg GG, Strachan JE, Lester RA. Invasive pneumococcal disease in the population of Victoria. The Medical Journal of Australia 2000; 173: S32–S35. 40Collignon PJ, Bell JM. Drug-resistant Streptococcus pneumonia: The beginning of the end for many antibiotics? The Medical Journal of Australia 1996; 164: 64–67. 41Caputo GM, Appelbaum PC, Hans HL. Infections due to penicillin-resistant Pneumococci. Archives of Internal Medicine 1993; 153: 1301–1310. 42Collignon PJ, Turnidge JD. Antibiotic resistance in Streptococcus pneumonia. Medical Journal of Australia 2000; 1973: S58–S64. 43Nicorti JP, Butler JC, Crutcher JM et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. New England Journal of Medicine 1998; 338: 1861–1868. 44Simberkoff MS, Cross AP, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients: Results of a Veterans Administration Co-operative Study. New England Journal of Medicine 1986; 315: 1318–1327. 45Ammann AJ, Schiffman G, Austrian R. The antibody responses to pneumococcal capsular polysaccharides in aged individuals. Proceedings of the Society for Experimental Biology and Medicine 1980; 164: 312–316. 46Woodward M. Pneumococcal vaccine in the elderly. Australian Journal of Hospital Pharmacy 1992; 22: 306–309. 47Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008; (1): CD000422. 48Butler JC, Breiman RF, Campbell JF, Lipman HB, Brown CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. Journal of the American Medical Association 1993; 270: 1826–1831. 49Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: A randomised single blind population-based trial. American Journal of Medicine 1997; 103: 281–290. 50 Victorian Government Department of Human Services. Influenza and Pneumococcal Pneumonia Immunisation 2001, Hospital and Community Program. Public Health Division, 2001. 51Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: Double blind, randomised and placebo controlled trial. British Medical Journal 2010; 340: c1004. 52Kelly H, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population criterions of the NNV: Comparison of influenza and pneumococcal vaccine programs for people aged 65 years and over. Vaccine 2004; 22: 2192–2198. 53 Australian Government Department of Health and Ageing. The Australian Immunisation Handbook, 9th edn. Canberra: National Health and Medical Research Council, 2008. 2008. 54 Ministry of Health. Immunisation Handbook 2014. Wellington: Ministry of Health, 2014. [Cited 9 March 2014.] Available from URL: http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-handbook-2006. 55Roche PW, Krause V, Cook H. Invasive pneumococcal disease in Australia, 2006. Communicable Diseases Intelligence 2008; 32: 18–30. 56MacIntyre CR, Ridda I, Gao Z et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS ONE 2014; 9: e94578. 57Williams WW, Hickson MA, Kane MA et al. Immunisation policies and vaccine coverage among adults: The risk for missed opportunities. Annals of Internal Medicine 1988; 108: 616–625, 55. 58Andrews RM, Lester RA. Improving vaccination coverage among older people in Victoria. Medical Journal of Australia 2000; 173: S45–S47. 59Bratzler DW, Houck PM, Jiang H et al. Failure to vaccinate Medicare inpatients. A missed opportunity. Archives Internal Medicine 2002; 162: 2349–2356. 60Goebel LUJ, Mufson MA. Influenza season triggers pneumococcal vaccination. Journal of the American Geriatrics Society 2006; 54: 1261–1264. 61Nichol KL, Zimmerman R. Generalists and subspecialist physicians' knowledge, attitudes and practice regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients. A nationwide survey. Archives of Internal Medicine 2001; 161: 2702–2708. 62Vella PP, McLean AA, Woodhour AF et al. Persistence of pneumococcal antibodies in human subjects following vaccination. Proceedings in Experimental Biology and Medicine 1980; 196: 435–438. 63Lackner TE, Hamilton RG, Hill JJ et al. Pneumococcal polysaccharide revaccination: Immunoglobulin G seroconversion, persistence, and safety in frail, chronically ill older subjects. Journal of the American Geriatrics Society 2003; 51: 240–245. 64Oxman MN, Levin MJ, Johnson GR, Schmader K, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 2271–2284. 65Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. Journal of the American Geriatrics Society 2007; 55: 1499–1507. 66 Department of Human Health and Services, AIDS and Communicable Diseases Branch. Tetanus notifications to the National Notifiable Diseases Surveillance System. Canberra: Commonwealth of Australia, 1995. 67Heath TC, Smith W, Capon AG, Hanion M, Mitchell P. Tetanus immunity in an older Australian population. Medical Journal of Australia 1996; 164: 593–596. 68Richardson JP, Knight AL. The prevention of tetanus in the elderly. Archives of Internal Medicine 1991; 151: 1712–1717. 69Fernandez R, Valcour V, Flynn B, Masaki K, Blanchette P. Tetanus immunity in long-term care facilities. Journal of the American Geriatrics Society 2003; 51: 1116–1119. 70Shohat T, Marva E, Sivan Y et al. Immunologic response to a single dose of tetanus toxoid in older people. Journal of the American Geriatrics Society 2000; 48: 949–951. 71 Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook, 10th edn. Canberra: Australian Government Department of Health, 2013: 402. [Cited 4 December 2014.] Available from URL: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home. Citing Literature Volume35, Issue1March 2016Pages 67-73 ReferencesRelatedInformation
Referência(s)